A Study to Prevent Rash in People Starting Alpelisib for the Treatment of Breast Cancer

Sponsor

Memorial Sloan Kettering Cancer Center (Other)

Overall Status

Recruiting

CT.gov ID

NCT05966584

Collaborator

AstraZeneca (Industry), Novartis Pharmaceuticals (Industry)

Enrollment

Locations

Arm

35.8

Anticipated Duration (Months)

Patients Per Site

0.2

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The researcher are doing this study to find out whether benralizumab is effective at preventing skin rashes caused by alpelisib in people who have metastatic breast cancer. Skin rash is a common side effect of alpelisib. Researchers think adding benralizumab to the standard-of-care hormone treatment and alpelisib may prevent the patient from getting a rash.

Condition or Disease	Intervention/Treatment	Phase
Breast Cancer	Drug: Benralizumab Drug: fulvestrant or AIs) and PI3K inhibition (alpelisib)	Phase 2

Study Design

Study Type:

Interventional

Anticipated Enrollment :

63 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Intervention Model Description:

A multi-center, open-label, phase 2 trialA multi-center, open-label, phase 2 trial

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

RETENTION: An Open-Label Phase 2 Trial of InteRlEukin (5) InhibiTion for the prEveNTION of Alpelisib Rash in Metastatic PIK3CA-mutant Hormone-Receptor Positive Breast Cancer

Actual Study Start Date :

Jul 6, 2023

Anticipated Primary Completion Date :

Jul 1, 2026

Anticipated Study Completion Date :

Jul 1, 2026

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Benralizumab and PI3K inhibition (alpelisib) Patients will receive fulvestrant or AIs and PI3K inhibition (alpelisib) per SOC (fulvestrant on days 1, 15, 29 and monthly thereafter; Ais on a daily continuous basis). Participants will receive one injection of benralizumab 30mg subcutaneously on day -1.	Drug: Benralizumab Benralizumab 30mg subcutaneously on day -1. Drug: fulvestrant or AIs) and PI3K inhibition (alpelisib) SOC endocrine therapy (fulvestrant or AIs) and PI3K inhibition (alpelisib)

Arm

Intervention/Treatment

Experimental: Benralizumab and PI3K inhibition (alpelisib)

Patients will receive fulvestrant or AIs and PI3K inhibition (alpelisib) per SOC (fulvestrant on days 1, 15, 29 and monthly thereafter; Ais on a daily continuous basis). Participants will receive one injection of benralizumab 30mg subcutaneously on day -1.

Drug: Benralizumab

Benralizumab 30mg subcutaneously on day -1.

Drug: fulvestrant or AIs) and PI3K inhibition (alpelisib)

SOC endocrine therapy (fulvestrant or AIs) and PI3K inhibition (alpelisib)

Outcome Measures

Primary Outcome Measures

proportion of subjects that have a grade ≤1 rash [4 weeks]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Histologically confirmed metastatic HR-positive, HER2-negative breast cancer. HR positive is defined by ER status >10% immunohistochemical (IHC) staining of any intensity.
Must be scheduled to receive SOC endocrine therapy (alpelisib plus fulvestrant or AIs)
Presence of one or more activating PIK3CA mutations in tumor tissue.
Measurable disease per RECIST v1.1 OR at least one predominantly lytic bone lesion must be present.
Written informed consent provided
Female or male ≥18 years of age
Eastern Cooperative Oncology Group performance status of 0 or 1.
Life expectancy ≥6 months.
Adequate organ and marrow function as defined below:

Hemoglobin ≥8.0 g/dL (without blood transfusion within 7 days of laboratory test used to determine eligibility)
Absolute neutrophil count ≥1.0 × 10^9 /L (without granulocyte colony stimulating factor support within 2 weeks of laboratory test used to determine eligibility)
Platelet count ≥50 × 10^9 /L (without transfusion within 2 weeks of laboratory test used to determine eligibility)
Total bilirubin (TB) ≤1.0 × institutional upper limit of normal (ULN; Patients with known Gilbert's disease who have TB ≤3 × ULN may be enrolled)
Aspartate transaminase/alanine transaminase ≤2.5 × ULN with normal alkaline phosphatase (≤5 × ULN for patients with liver metastases) OR ≤1.5 × ULN in conjunction with alkaline phosphatase >2.5 × ULN
Creatinine ≤1.5 mg/dL

Able to swallow oral medication.
Willing to be randomized to any of the treatment arms and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations.
Women must be of postmenopausal status. Postmenopausal status is defined by any one of the following criteria:

Prior bilateral oophorectomy
Age ≥60 years
Age <60 years and amenorrheic for at least 12 months (spontaneous cessation of menses for 12 consecutive months or more in the absence of chemotherapy, tamoxifen, toremifene, or ovarian suppression) and follicle-stimulating hormone and estradiol levels in the postmenopausal range without an alternative cause.

Exclusion Criteria:

Known hypersensitivity to alpelisib, fulvestrant or AIs, benralizumab, cetirizine, or to any of the excipients of alpelisib, fulvestrant or AIs, benralizumab, or cetirizine.
Concurrent malignancy (basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or cervical cancer in situ that have undergone curative intent therapy are allowed)
Individuals with impaired decision making capacity.
Concurrent use of another investigational drug or device for the rash (i.e., outside of study treatment) during, or within 4 weeks of treatment.
Known use of anti-IL-5 agents or other biologics for the treatment of asthma which are known to decrease blood eosinophil levels within the past 12 weeks.
Known history of anaphylaxis to benralizumab therapy.
A helminthic parasitic infection diagnosed within 24 weeks prior to the first treatment, and assent when applicable, was obtained that had not been treated with, or has failed to respond to, standard of care therapy.
Known history of human immunodeficiency virus (HIV) infection or current chronic or active hepatitis B or C infection requiring treatment with antiviral therapy.
Active infection that would impair the ability of the patient to receive study treatment.
Women who are pregnant or breast-feeding.
Any condition which, in the investigator's opinion, makes the subject unsuitable for trial participation.
Oral corticosteroids at a dose of ≥20mg/day prednisone or equivalent within 14 days expected to continue during alpelisib therapy.
More than 2 lines of endocrine-based therapy in the metastatic setting.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Stanford University	Stanford	California	United States	94305
2	Dana Farber Cancer Institute	Boston	Massachusetts	United States	02115
3	Memorial Sloan Kettering Basking Ridge (All Protocol Activities)	Basking Ridge	New Jersey	United States	07920
4	Memorial Sloan Kettering Monmouth (Limited Protocol Activities)	Middletown	New Jersey	United States	07748
5	Memorial Sloan Kettering Cancer Center @ Suffolk - Commack (Limited Protocol Activities)	Commack	New York	United States	11725
6	Memorial Sloan Kettering Westchester (All Protocol Activities)	Harrison	New York	United States	10604
7	Memorial Sloan Kettering Cancer Center (All Protocol Activities)	New York	New York	United States	10065
8	Memorial Sloan Kettering Rockville (Limited Protocol Activities)	Rockville Centre	New York	United States	11570
9	Memorial Sloan Kettering Nassau (Limited Protocol Activities)	Uniondale	New York	United States	11553